Citi cuts Ypsomed to 'neutral' after strong share-price run

By Reuters News

** Citi cuts Swiss drug-delivery device maker Ypsomed YPSN.S to "neutral" from "buy" after the stock's recent re-rating

** Shares are up 21% over the last month and 34% year-to-date

** Citi remains positive on Ypsomed's medium-term growth prospects, but sees a more balanced risk-reward profile at the current valuation, with few near-term catalysts before FY 2026/27 results next May

** It continues to view Ypsomed as a "high-quality asset" thanks to its attractive exposure to biologics, biosimilars and incretin therapies

** Following the company's H1 results and guidance hike, Citi increases its EPS estimates by 3-5% for fiscal years 2026/27-2030/31

** It also raises its PT to CHF 450 ($537) from CHF 425

($1 = 0.8384 Swiss francs)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk